snakebite treatment protocol
TRANSCRIPT
-
8/10/2019 Snakebite Treatment Protocol
1/37
Snakebite Protocol
-
8/10/2019 Snakebite Treatment Protocol
2/37
Contents
Page
First Aid Treatment Protocol 4Recommended Method Do it R.I.G..T.! 4
Discarded Methods" To#rni$#ets %
Discarded Methods" C#tting and S#ction %
&ashing the &o#nd %
Discarded Methods" 'lectrical and Cr(othera)( *
+e,er Methods Considered Ina))licable to India" PIM *
First Aid Research -
Snakebite Preention and /cc#)ational Adice 0
Snakebite Treatment Protocol 1Patient Arrial 1
Diagnosis Phase" General Princi)les 1
Pain 1
andling To#rni$#ets 23
Diagnosis Phase" Inestigations 23
3 Min#te &hole 5lood Clotting Test 23
Diagnosis Phase" S(m)toms 22
General Signs and S(m)toms o6 7i)erine 'nenomation 22
General Signs and S(m)toms o6 'la)id 'nenomation 2
8ate /nset 'nenoming 2Anti Snake 7enom 2
AS7 Administration Criteria 29
Preention o6 AS7 Reactions : Pro)h(lactic Regimes 24
AS7 Administration Doses 2%
AS7 Test Doses 2*
AS7 Dosage in 7ictims Re$#iring 8i6e Saing S#rger( 2*
Snakebite in Pregnanc( 2*
7ictims &ho Arrie 8ate 2-
AS7 Reactions 2-
+e#roto;ic 'nenomation 20
Recoer( Phase 21Re)eat Doses" Anti aemostatic 21
Rec#rrent 'nenomation 3
Anti aemostatic Ma;im#m AS7 Dosage G#idance 3
Re)eat Doses +e#roto;ic 2
()otension 2
S#rgical Interention 2
Persistent and Seere 5leeding
-
8/10/2019 Snakebite Treatment Protocol
3/37
Renal Fail#re and AS7 9
'ssential Dr#g and '$#i)ment Pro6ile
6or a Primar( Centre *
Contents
A))endices
Page
A))endi; 2 First Aid Re6erence > Treatment Re6erences 1
A))endi; S#))ort Factors to 'nhance Protocols 9*
-
8/10/2019 Snakebite Treatment Protocol
4/37
First Aid Treatment Protocol
To enable them to reach the nearest medical facility in the best possible condition.
Much of the first aid currently carried out is ineffective and dangerous (Simpson, 2006).
ndian research has agreed on the follo!ing recommended method having vie!ed andconsidered the available research and concluded that other methods are not appropriate
for the conditions in ndia.
Recommended Method 6or India
The first aid being currently recommended is based around the mnemonic"
?Do it R.I.G..T.@
t consists of the follo!ing"
R. Reass#re the )atient. -3B o6 all snakebites are 6rom non enomo#s s)ecies. /nl( %3B o6 bites b( enomo#s
s)ecies act#all( enenomate the )atient
I Immobilise in the same ,a( as a 6ract#red limb.
-
8/10/2019 Snakebite Treatment Protocol
5/37
Traditional Methods to 5e Discarded
To#rni$#ets
The use of tight tourni#uets made of rope, belt, string or cloth have been traditionally
used to stop venom flo! into the body follo!ing sna$ebite. 'o!ever, they have thefollo!ing dra!bac$s and problems"
is$ of schemia and loss of the limb (arrell, *+++).
ncreased is$ of &ecrosis !ith %- of the medically significant sna$es of ndia.
(airly, *+2+) (/ugh et al, *+1) (arrell, *++-).
ncreased ris$ of massive neurotoic bloc$ade !hen tourni#uet is released (att,
*+).
is$ of embolism if used in viper bites. /ro3coagulant en4ymes !ill cause clotting
in distal blood. n addition, the effect of the venom in causing vasodilation
presents the danger of massive hypotension !hen the tourni#uet is released.
They do not !or$5 (Tun /e *+1) (hin37hn 8!in *+%). 9enom !as not slo!ed
by the tourni#uet in several eperimental studies, as !ell as in field conditions.
7ften this is because they are tied on the lo!er limb or are incorrectly tied (att,
200:) (;maral, *++) (&ishio$a, 2000).
They give patients a false sense of security, !hich encourages them to delay their
ush, 2000) (>ush, 200%). There has been some evidence that
these devices increase envenomation as they inhibit natural oo4ing of venom from
the !ound (;lberts et al, 200%). n addition, they have been sho!n to increase thelocal effects of necrosis (;lberts et al, 200%).
&ashing the &o#nd
9ictims and bystanders often !ant to !ash the !ound to remove any venom on the
surface. This should not be done as the action of !ashing increases the flo! of venominto the system by stimulating the lymphatic system (?ray, 200:).
-
8/10/2019 Snakebite Treatment Protocol
6/37
'lectrical Thera)( and Cr(othera)(
@lectric shoc$ therapy for sna$ebite received a significant amount of press in the *+0As.
The theory behind it stated that applying an electric current to the !ound denatures the
venom (?uderian et al, *+6). Much of the support for this method came from letters touc$nall, *++*) (roegal et al, *+6).
The research sho!ed ho!ever that the venom is not denatured (Bavis et al, *++2). naddition, it has been demonstrated that the electric shoc$ has no beneficial effect (Bart et
al, *++*) ('o!e et al, *+) (ussell, *+1) (ussell, *+1a) (Snyder et al, *+1) ('ardy,
*++2). t has no! been abandoned as a method of first aid.
=ryotherapy involving the application of ice to the bite !as proposed in the *+-0As
(Stan$e *+-*) (?lass, *+*). t !as subse#uently sho!n that this method had no benefit
and merely increased the necrotic effect of the venom.
+e,er Methods Considered Ina))licable in the Indian Conte;t
Press#re Immobilisation Method PIM
/ressure mmobilisation has gained some supporters on television and in the herpetology
literature. Some medical tetboo$s have referred to it. They have not ho!ever, revie!edthe research, nor considered /MAs applicability in the ndian contet5
/M !as developed in ;ustralia in *+1% by Sutherland (Sutherland *+*). 'is
research involved tying mon$eys to !ooden frames and in
-
8/10/2019 Snakebite Treatment Protocol
7/37
n addition, pressure bandages should not be used !here there is a ris$ of local
necrosis, that is in %- of the medically significant sna$es of ndia (>ush, 200%).
Therefore, ndian rural !or$ers !ould need"
*) To be in possession of crepe bandages and splints.
2) or the victim to immediately drop to the ground !hen bitten.:) To have to be in pairs as the bystander must tie the bandage and
splint, !hile the victim remains immobile.%) To be able to tie the bandage to the correct level of pressure depending
on !hether an upper or lo!er limb !as involved, !hen only *:D
of emergency room doctors could achieve this.-) ;nd not to have to !al$ for more than *0 minutes.
For the aboe reasons Press#re Immobilisation is not recommended 6or #se in
India.
F#rther First Aid ResearchThere has been some initial research that has suggested that a E/ressure /ad or MonashTechni#ueA may have some benefit in the first aid treatment of sna$ebite (;n$er et al,
*+2) (Tun /e et al, *++-) (Tun /e et al, 2000). n this method, a hard pad of rubber or
cloth is applied directly to the !ound in an attempt to reduce venom entering the system.
This method should be sub
-
8/10/2019 Snakebite Treatment Protocol
8/37
Snakebite Preention > /cc#)ational Risk
The normal perception is that rural agricultural !or$ers are most at ris$ and the bites
occur first thing in the morning and last thing at night. 'o!ever, this is of very little
practical use to rural !or$ers in preventing sna$ebite since it ignores the fact that often
sna$ebites cluster around certain bio3mechanical activities, in certain geographic areas, atcertain times of the day.
?rass3cutting remains a ma
-
8/10/2019 Snakebite Treatment Protocol
9/37
-
8/10/2019 Snakebite Treatment Protocol
10/37
Snake 5ite Treatment Protocol
Patient Assessment Phase" /n arrial.Beal !ith any life threatening symptoms on presentation. i.e. ;ir!ay, >reathing and=irculation.
f there is evidence of a bite, !here the s$in has been bro$en, give Tetanus Tooid
outine use of anti3biotic is not necessary, although it should be considered if there isevidence of cellulitis or necrosis.
Diagnosis Phase" General Princi)les
here possible identify the sna$e responsible. Sna$e colouration is a very
unreliable means of determining species as is most of the advice given
concerning pupil shape and scalation. 'ave the victim carefully bring thesna$e to hospital if it has been $illed.
All )atients ,ill be ke)t #nder obseration 6or a minim#m o6 4 ho#rs. n some countries bite mar$s have limited use in determining species
(&ishio$a et al, *++-) (&orris, *++-). 'o!ever, in ndia bite mar$s are of no
use in identifying if a species is venomous or not. Many non venomous
species leave
-
8/10/2019 Snakebite Treatment Protocol
11/37
andling To#rni$#ets=are must be ta$en !hen removing tight tourni#uets tied by the victim. Sudden removal
can lead to a massive surge of venom leading to neurological paralysis, hypotension due
to vasodilation etc.
>efore removal of the tourni#uet, test for the presence of a pulse distal to the
tourni#uet. f the pulse is absent ensure a doctor is present before removal.
>e prepared to handle the complications such as sudden respiratory distress or
hypotension. f the tourni#uet has occluded the distal pulse, then a blood pressurecuff can be applied to reduce the pressure slo!ly.
Diagnosis Phase" Inestigations
3 Min#te &hole 5lood Clotting Test 3&5CT
=onsidered the most reliable test of coagulation and can be carried out at the bedside
!ithout specialist training. t can also be carried out in the most basic settings. t is
significantly superior to the Ecapillary tubeA method of establishing clotting capabilityand is the preferred method of choice in sna$ebite.
; fe! mls of fresh venous blood is placed in a ne!, clean and dry glass vessel and left
at ambient temperature for 20 minutes. The vessel ideally should be a small glass testtube. t is important that the tube is clean, glass and dry as the mechanism under revie!
is the contact clotting mechanism. The use of plastic bottles, tubes or syringes !ill give
false readings and should not be used.
The glass vessel should be left undisturbed for 20 minutes and then gently tilted, notshaken. f the blood is still li#uid then the patient has incoagulable blood. The vesselmust not have been !ashed !ith detergent as this !ill inhibit the contact element of the
clotting mechanism.
The test should be carried out every :0 minutes from admission for three hours and thenhourly after that. f incoagulable blood is discovered, the 6 hourly cycle !ill then be
adopted to test for the re#uirement for repeat doses of ;S9.
7ther Fseful Tests depending on availability 'aemoglobin /=9 /latelet =ount /T ;/TT B/ B3Bimer
/eripheral Smear
Frine Tests for /roteinuria >= 'aemoglobinuria Myoglobinuria
>iochemistry for Serum =reatinine Frea /otassium
7ygen Saturation />/ /ostural >lood /ressure
@=? G3ay =T Fltrasound (The use of G3ay and ultrasound are of
unproven benefit, apart from identification of bleeding in 9iperine bites).
-
8/10/2019 Snakebite Treatment Protocol
12/37
Diagnosis Phase" S(m)toms
General
There are a great many myths surrounding sna$e symptoms. The table belo! summarises
the evidence based situation. 'aemostatic abnormalities are prima facie evidence of a
9iper bite. =obras and raits do not cause haemostatic disturbances.
Sa! Scaled 9ipers do not cause renal failure !hereas ussells 9iper and 'ump3nosed
/itviper do.
ussells 9iper can also manifest neurotoic symptoms in a !ide area of ndia. This can
sometimes cause confusion and further !or$ is necessary to establish ho! !ide this area
might be. The neurotoic symptoms in ussells 9iper are believed to be pre synaptic orrait li$e in nature. t is for this reason that a doubt is epressed over the response of
both species to &eostigmine (See belo! for use of neostigmine).
Feat#re Cobras Hraits R#ssells
7i)er
Sa,
Scaled
7i)er
#m)
+osed
7i)er
8ocal Pain= Tiss#e Damage 'S +/ 'S 'S 'S
Ptosis= +e#rological Signs 'S 'S 'SE +/ +/
aemostatic abnormalities +/ +/E 'S 'S 'S
Renal Com)lications +/ +/ 'S +/ 'S
Res)onse to +eostigmine 'S +/J +/J +/ +/
Res)onse to AS7 'S 'S 'S 'S +/
General signs and s(m)toms o6 7i)erine enenomation
S!elling and local pain.
Tender enlargement of local lymph nodes as large molecular !eight 9iper venom
molecules enter the system via the lymphatics.
>leeding from the gingival sulci and other orifices.
@pistais.
9omiting (alantri S/ et al. 2006).
;cute abdominal tenderness !hich may suggest gastro3intestinal or retro
peritoneal bleeding.
'ypotension resulting from hypovolaemia or direct vasodilation.
8o! bac$ pain, indicative of a early renal failure or retroperitoneal bleeding,
although this must be carefully investigated as many rural !or$ers involved in
pic$ing activities complain of bac$ pain generally.
The s$in and mucous membranes may sho! evidence of petechiae, purpura
ecchymoses.
-
8/10/2019 Snakebite Treatment Protocol
13/37
The passing of reddish or dar$3bro!n urine or declining or no urine output.
8ateralising neurological symptoms and asymmetrical pupils may be indicative of
intra3cranial bleeding.
Muscle pain indicating rhabdomyolysis.
/arotid s!elling, con
-
8/10/2019 Snakebite Treatment Protocol
14/37
identifying the sna$e species, in the absence of the dead sna$e. t !ould be impossible for
the physician to determine !hich type of Monovalent ;S9 to employ in treating the
patient.
;n ndian medical college is currently !or$ing to develop @n4yme 8in$ed mmuno
Sorbent ;ssay testing for sna$e species and level of envenomation, although it !ill ta$emany years before a reliable and effective $it is available to doctors.
There are $no!n species such as the 'ump3nosed pitviper (Hypnale hypnale) !herepolyvalent ;S9 is $no!n to be ineffective. n addition, there are regionally specific
species such as Sochure$As Sa! Scaled 9iper (Echis carinatus sochureki) in a=T or visiblespontaneous systemic bleeding, gums etc.
urther laboratory tests for thrombocytopenia, 'b abnormalities, /=9,peripheral smear etc provide confirmation, but 20>=T is paramount.
-
8/10/2019 Snakebite Treatment Protocol
15/37
@vidence of neurotoicity" ptosis, eternal ophthalmoplegia, muscle paralysis,
inability to lift the head etc.
The above t!o methods of establishing systemic envenomation are the primary
determinants. They are simple to carry out, involving bedside tests or identification of
visible neurological signs and symptoms. n the ndian contet and in the vast ma
-
8/10/2019 Snakebite Treatment Protocol
16/37
The dose for children is 0.*30.:mg$g of antihistamine 9 and 2mg$g of
hydrocortisone 9. ;ntihistamine should be used !ith caution in pediatric
patients.
0.2-30.:mg adrenaline *"*000 given subcutaneously.
The conclusion in respect of prophylactic regimens to prevent anaphylactic reactions, is
that there is no evidence from good #uality randomi4ed clinical trials to support their
routine use. f they are used then the decision must rest on other grounds, such as politicalpolicy in the case of ?overnment 'ospitals, !hich may opt for a maimum safety policy,
irrespective of the lac$ of definitive trial evidence.
f the victim has a $no!n sensitivity to ;S9, pre3medication !ith adrenaline,hydrocortisone and anti3histamine may be advisable, in order to prevent severe reactions.
AS7 Administration" Dosage
n the absence of definitive data on the level of envenomation, such as provided by@8S; testing (?reen!ood et al, *+1%) (Thea$ston et al, *+11) ('o et al, *+6),
symptomology is not a useful guide to the level of envenomation. ;ny ;S9 regimenadopted is only a best estimate. hat is important is that a single protocol is established
and adhered to, in order to enable results to be reliably revie!ed.
The recommended dosage level has been based on published research that ussells 9iper
in
-
8/10/2019 Snakebite Treatment Protocol
17/37
+/ AS7 T'ST D/S' M
-
8/10/2019 Snakebite Treatment Protocol
18/37
/regnant !omen are treated in eactly the same !ay as other victims. The same dosage
of ;S9 is given.
The victim should be referred to a gynaecologist for assessment of any impact on the
foetus.
7ictims &ho Arrie 8ate; fre#uent problem is victims !ho arrive late after the bite, often after several days,usually !ith acute renal failure. Should the clinician administer ;S9J The $ey
determining factor is, are there any signs of current venom activityJ 9enom can only be
neutralised if it is unattached5 /erform a 20>=T and determine if any coagulopathy ispresent. f coagulopathy is present, administer ;S9. f no coagulopathy is evident treat
any renal failure by reference to a nephrologist and dialysis.
n the case of neurotoic envenoming !here the victim is evidencing symptoms such as
ptosis, respiratory failure etc, it is probably !ise to administer * dose of 3*0 vials of;S9 to ensure that no unbound venom is present. 'o!ever, at this stage it is li$ely that
all the venom is bound and respiratory support or normal recovery !ill be the outcome.
AS7 Reactions;naphylais is life3threatening, but despite the reluctance in giving ;S9 due toreactions (alantri et al, 200-), if the correct protocol is follo!ed, it can be effectively
treated and dealt !ith. ;naphylais can be rapid onset and can deteriorate into a life3
threatening emergency very rapidly. ;drenaline should al!ays be immediatelyavailable.
The patient should be monitored closely (/eshin et al, *++1) and at the first sign of anyof the follo!ing"
Frticaria, itching, fever, sha$ing chills, nausea, vomiting, diarrhoea, abdominal cramps,
tachycardia, hypotension, bronchospasm and angio3oedema
2. AS7 ,ill be discontin#ed
. 3.%mg o6 2"2333 adrenaline ,ill be gien IM
=hildren are given 0.0*mg$g body !eight of adrenaline M.
n addition, to provide longer term protection against anaphylactoid reaction, *00mg ofhydrocortisone and an '* antihistamine, such as /henimarine maleate can be used at
22.-mg 9 or /rometha4ine '=l can be used at 2-mg M, or *0mg chlorphenirmarine
maleate if available, !ill be administered 9.
The dose for children is of /henimarine maleate at 0.-mg$g day 9 or
/rometha4ine '=l can be used at 0.:30.-mg$g M or 0.2mg$g ofchlorphenimarine maleate 9 and 2mg$g of hydrocortisone 9.
-
8/10/2019 Snakebite Treatment Protocol
19/37
;ntihistamine use in pediatric cases must be deployed !ith caution.
f after *0 to *- minutes the patientKs condition has not improved or is !orsening, a
second dose of 0.- mg of adrenalin *"*000 M is given. This can be repeated for a third
and final occasion but in the vast ma
-
8/10/2019 Snakebite Treatment Protocol
20/37
The follo!ing measures are useful oblood coagulability is usually restored in 6 hours. /rincipal test is 20>=T
c) /ost synaptic neurotoic envenoming such as the =obra may begin to improve as early
as :0 minutes after antivenom, but can ta$e several hours.d) /resynaptic neurotoic envenoming such as the rait usually ta$es a considerable time
to improve reflecting the need for the body to generate ne! acetylcholine emitters.
e) ;ctive haemolysis and rhabdomyolysis may cease !ithin a fe! hours and the urinereturns to its normal colour.
f) n shoc$ed patients, blood pressure may increase after :0 minutes.
Re)eat Doses" Anti aemostaticn the case of anti haemostatic envenomation, the ;S9 strategy !ill be based around a
si hour time period. hen the initial blood test reveals a coagulation abnormality, the
initial ;S9 amount !ill be given over * hour.
&o additional ;S9 !ill be given until the net =lotting Test is carried out. This is due to
the inability of the liver to replace clotting factors in under 6 hrs.
-
8/10/2019 Snakebite Treatment Protocol
21/37
;fter 6 hours a further coagulation test should be performed and a further dose should be
administered in the event of continued coagulation disturbance. This dose should also be
given over * hour. =T tests and repeat doses of ;S9 should continue on a 6 hourlypattern until coagulation is restored, unless a species is identified as one against !hich
/olyvalent ;S9 is not effective.
The repeat dose should be -3*0 vials of ;S9 i.e. half to one full dose of the original
amount. The most logical approach is to administer the same dose again, as !as
administered initially. Some ndian doctors ho!ever, argue that since the amount ofunbound venom is declining, due to its continued binding to tissue, and due to the !ish to
conserve scarce supplies of ;S9, there may be a case for administering a smaller second
dose. n the absence of good trial evidence to determine the ob
-
8/10/2019 Snakebite Treatment Protocol
22/37
-
8/10/2019 Snakebite Treatment Protocol
23/37
ussells 9iper bites are $no!n to cause acute pituitary adrenal insufficiency (Tun /e et
al, *+1) (@apen et al *+16). This condition may contribute to shoc$. ollo!3up chec$son $no!n ussells 9iper victims need to ensure that no long term pituitary se#uelae are
evident.
S#rgical Interentionhilst there is undoubtedly a place for a surgical debridement of necrotic tissue, the use
of fasciotomy is highly #uestionable. The appearance of (Hoseph, 200:)"
/ain on passive stretching
/ain out of proportion
/ulselessness
/allor
/arasthesia
/aralysis
!ith significant s!elling in the limb, can lead to the conclusion that theintracompartmental pressure is above %0 mm of mercury and thus re#uires a fasciotomy.
asciotomy is re#uired if the intracompartmental pressure is sufficiently high to cause
blood vessels to collapse and lead to ischemia. asciotomy does not remove or reduceany envenomation.
There is little ob
-
8/10/2019 Snakebite Treatment Protocol
24/37
-
8/10/2019 Snakebite Treatment Protocol
25/37
Snakebite Management in Primar(=Comm#nit(=Dis)ensar( ealth
Care Centres
; $ey ob Assessment
/atient should be placed under observation for 2% hours
The sna$e, if brought, should be carefully eamined and compared to the sna$e
identification material./ain management should be considered.
20>=T in clean, ne!, dry, glass test tubes should be carried out every :0 minutes forthe *st: hours and then hourly after that.
;ttention should be paid for any visible neurological symptoms.Severe, current, local s!elling should be identified
f no symptoms develop after 2% hours the patient can be discharged !ith a T.T.
'nenomationK aemoto;ic
f the patient has evidence of haemotoic envenomation, determined by 20>=T, then
3*0 vials of ;S9 are administered over * hour.;drenaline is made ready in t!o syringes of 0.-mg *"*000 for M administration if
symptoms of any adverse reaction appear. f symptoms do appear, ;S9 is temporarily
suspended !hile the reaction is dealt !ith and then recommenced.
Re6erral Criteria
7nce the ;S9 is finished and the adverse reaction dealt !ith the patient should be
automatically referred to a higher centre !ith facilities for blood analysis to determineany systemic bleeding or renal impairment.
The 6 hour rule ensures that a si hour !indo! is no! available in !hich to transport thepatient.
'nenomationK +e#roto;ic
f the patient sho!s signs of neurotoic envenomation 3*0 vials are administered over *hour.
;drenaline is made ready in t!o syringes of 0.-mg *"*000 for M administration ifsymptoms of any adverse reaction appear. f symptoms do appear, ;S9 is temporarily
suspended !hile the reaction is dealt !ith and then recommenced.
-
8/10/2019 Snakebite Treatment Protocol
26/37
; neostigmine test is administered using *.-32.0mg of neostigmine M plus 0.6mg of
atropine 9. ;n ob
-
8/10/2019 Snakebite Treatment Protocol
27/37
allo!ing the tongue to fall bac$ and bloc$ the air!ay, !ithout triggering the gagging
refle. mprovised &asopharyngeal tubes can be made by cutting do!n si4e -
endotracheal tubes to the re#uired length i.e. from the tragus to the nostril. &/ tubesshould be prepared and $ept !ith the sna$ebite $it in the /'=. This is preferable as the
patient may !ell be unable to perform a nec$ lift but still remain conscious and breathing.
The danger !ill be that respiratory failure !ill occur after the patient has left the /'=and before arriving at the eventual institution. n that case the patient !ill be pre3prepared
for the use of a resuscitation bag by the use of &/ tubes.
n the unconscious patient, a 8aryngeal Mas$ ;ir!ay or preferably a 8aryngeal Tube
;ir!ay should be inserted before referral !hich !ill enable more effective ventilatory
support to be provided !ith a resuscitation bag until the patient reaches an institution
!ith the facility of mechanical ventilation..
5asic Minimal > 'ssential Dr#g and '$#i)ment Pro6ile 6or a Primar(
Centre
n order to be able to effectively respond to sna$ebite, the primary care centre needs adrug and e#uipment profile that supports sna$ebite treatment. 7ften the level of s$ill to
design such a profile is not readily available. ?ood guidelines are therefore re#uired fordoctors and government procurement groups as to ho! to e#uip a primary centre for its
role.
Antienom = Anti Snake 7enom
The type of ;9;S9 used !ill be determined by availability, cost and effectiveness of the
cold chain. 8yophilised ;9;S9, in po!dered form has a shelf life of - years andre#uires merely to be $ept out of direct sunlight. 8i#uid ;9;S9, !hich is easier to
administer, has a shelf life of t!o years and re#uires refrigeration.
n this instance the holding #uantity can be established using the follo!ing e#uation"(d G *.2) t !here"
Onumber of envenomings on average per monthd O the maimum number of vials li$ely to be applied at the /'= to a single patient
t O length of time normally eperienced for replenishment in months.
Suppose !e are dealing !ith a /'= !ith t!o envenomings per month then O2 The
maimum dose re#uired per patient determines a $ey part of usage, so for eample, in
ndia the maimum dose for a patient at a /'= !ould be 2 doses of *0 vials for a
neurotoic patient, so d O 20. *.2 represents the safety factor to ensure greater thanminimal stoc$ is available. The restoc$ing time in months is represented by t. f the
restoc$ing period is 2 months for ;9;S9 to be replaced the e#uation !ould re#uire 2 G
20 G *.2 G 2 O +6 vials !ould be the ;9;S9 base stoc$ amount.
-
8/10/2019 Snakebite Treatment Protocol
28/37
-
8/10/2019 Snakebite Treatment Protocol
29/37
The F#t#re o6 Snakebite Management in India
t is recognised that this protocol represents the best available information and guidelinesfor dealing !ith sna$ebite in ndia. t !ill be constantly updated to reflect the best
evidence based research that emerges during its use.
-
8/10/2019 Snakebite Treatment Protocol
30/37
A))endi; 2
Re6erences
First Aid
;lberts M>, Shalit M, 8ogalbo , Suction for venomous sna$ebite" a study of Qmoc$
venom in a human modelQ ;nn @merg Med. 200% ebC%:(2)"**36.
;maral =, =ampolina B, Bias M>, >ueno =M, e4ende &;. Tourni#uetineffectiveness to reduce the severity of envenoming after =rotalus durissus sna$e bite in
>elo 'ori4onte, Minas ?erais, >ra4il. *++ Toicon. MayC:6(-)"0-3.
;n$er 8, Staffon ?, 8oiselle BS, ;n$er M, etarding the upta$e of moc$ venom in
humans. =omparison of three first aid treatments Medical Hournal of ;ustralia *+2.
2*232*%
>uc$nall &, @lectrical Treatment of venomous bites and stings" a mini revie!. Toicon
*++*C 2+" :+13%00
>ush S/, Sna$ebite suction devices donAt remove venom" They ush S/, ?reen SM, 8aac$ T;, 'ayes , =ard!ell MB, Tanen B;, /ressuremmobilisation delays mortality and increases intracompartmental pressure after artificial
intramuscular rattlesna$e envenomation in a porcine model ;nnals of @mergency
Medicine 200%C %%(6)"-++360%
=urrie >. /ressure3immobili4ation first aid for sna$ebite 3 fact and fancy. *++: G
nternational =ongress for Tropical Medicine and Malaria. Homtien, /attaya, Thailand 2+
&ov3% Bec. Toxicon *++2C :* ()"+:*3+:2.(abstract).
Bavidson TM, Sam splint for !rap and immobilisation of sna$ebite. Hournal ofilderness Medicine 200*C (*2)" 2063201
Bavis B, >ranch , @gen &>, ussell @, ?errish , ;uerbach /S, The effect of an
electrical current on sna$e venom toicity. Hournal of ilderness Medicine *++2C (:)" %3-:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstracthttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9655642&query_hl=2&itool=pubmed_docsumhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstracthttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstracthttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstracthttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9655642&query_hl=2&itool=pubmed_docsumhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstracthttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14747806&itool=pubmed_Abstract -
8/10/2019 Snakebite Treatment Protocol
31/37
-
8/10/2019 Snakebite Treatment Protocol
32/37
ussell @ ;nother arning about @lectroshoc$ for Sna$ebite /ostgrad Med *+1a C2 "
:2
Sharma S, =happuis , Hha &, >ovier /;, 8outan 8, oirala S.mpact of sna$e bites
and determinants of fatal outcomes in southeastern &epal. ;m H Trop Med 'yg.
;ugC1*(2)"2:%3.
Simpson B Sna$ebite" ecent ;dvances 2006 in Medicine Fpdate 2006 @d Sahay >
The ;ssociation of /hysicians of ndia 6:+36%:
Snyder ==, Murdoc$ T, hile ?8, uitu H @lectric Shoc$ Treatment for Sna$ebite
8ancet *++C *"*022
Sutherland, =oulter ;, 'arris B, ationalisation of first aid methods for elapid
sna$ebite 8ancet *+1+C i "*:3*6
Sutherland S, 'arris B, =oulter ;, 8overing @, irst aid for =obra (&aur$e =.
;cute and chronic pituitary failure resembling SheehanKs syndrome follo!ing bites by
ussellKs viper in >urma. 8ancet*+1C(-62)"16:31.
Tun /e, ;ye ;ye Myint, hin @i 'an et al, 8ocal =ompression pads as a first aid measure
for victims of bites by ussells 9iper (Baboia russelii siamensis) in Myanmar. Transoyal Society of Trop Medicine *++-C +"2+:32+-
Tun /e, Sann Mya, ;ye ;ye Myint, &u &u ;ung, hin ;ye yu, Tin 7o, ield Trials of@fficacy of 8ocal =ompression mmobilisation irst ;id Techni#ue in ussells 9iper
(Baboia russelii siamensis) >ite /atients Southeast ;sian H Trop Med /ublic 'ealth
2000C:*(2)":%63:%
arrell B;=linical Toicology of Sna$ebite in ;sia *++- in 'andboo$ of =linical
Toicology of ;nimal 9enoms and /oisons @d hite H Meier H. == /ress
arrell, B.;. (@d). *+++. '7S@;7 ?uidelines for The =linical Management of
Sna$ebite in the Southeast ;sian egion. S@ ;sian H. Trop. Med. /ub. 'lth. :0, Suppl *,
*3-.
att ?, /adre 8, Tua4on 8, Thea$ston B?, 8aughlin 8. Tourni#uet ;pplication after
=obra >ite" Belay in the 7nset of &eurotoicity and the Bangers of Sudden elease. ;m
H Trop Med 'yg *+C 1" 6*3622
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15306717&query_hl=6&itool=pubmed_docsumhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tun-Pe%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Phillips+RE%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Warrell+DA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Moore+RA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tin-Nu-Swe%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Myint-Lwin%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Burke+CW%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15306717&query_hl=6&itool=pubmed_docsumhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tun-Pe%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Phillips+RE%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Warrell+DA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Moore+RA%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Tin-Nu-Swe%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Myint-Lwin%22%5BAuthor%5Dhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&itool=pubmed_Abstract&term=%22Burke+CW%22%5BAuthor%5D -
8/10/2019 Snakebite Treatment Protocol
33/37
Treatment
;gra!al /&, ;##ara!al ;&, ?upta B, >ehera B, /rabha$ar S, Hindal S, Management
of espiratory ailure in Severe &europaralytic Sna$e @nvenomation &eurol ndia. 200*C%+(*)"2-32
;gar!al , ;ggar!al ;&, ?upta B, >ehera B, Hindal S. 8o! dose of sna$e antivenomis as effective as high dose in patients !ith severe neurotoic sna$e envenoming. @merg
Med H. 200-C22(6)":+13+.
;merican ;ssociation of ;llergy, ;sthma, and mmunology. Media resources" position
statement 26. The use of epinephrine in the treatment of anaphylais.
!!!.aaaai.orgmediaresourcesadvocacystatementsps26.stm (accessed ;pr 200:).
;nderson H, 8inas ST, >erns ;S, 'enrich 8, Miller T, ?abo! /;, Schrer , &on3
oliguric acute renal failure. &e! @ng Hournal of Medicine. *+11C 2+6" **:%3**:
>omb >S, oy S, uma!at B=, >har
-
8/10/2019 Snakebite Treatment Protocol
34/37
alantri S,Singh ;, Hoshi , Malamba S, 'o =, @4oua H, Morgan M. =linical /redictors
of in3hospital mortality in patients !ith sna$ebite" a retrospective study from a ruralhospital in central ndia Tropical medicine and nternational health. 200-C **(*)" 223:0
ularatne S;.=ommon $rait (>ungarus caeruleus) bite in ;nuradhapura, Sri 8an$a" aprospective clinical study, *++63+. /ostgrad Med H. 2002 C1(+*+)"21630.
Mc8ean3Too$e ; / =, >ethune = ;, ay ; =, Spic$ett ? /,;drenaline in the treatmentof anaphylais" !hat is the evidenceJ >MH. 200:C :21" *::23*::-
Myint38!in, /hillips @, Tun3/e, arrell B;, Tin3&u3S!e, Maung Maung 8ay, >ites by
ussells 9iper (9ipera russelli siamensis) in >urma" 'aemostatic vascular and renaldisturbances and response to treatment. 8ancet. *+-C %61" *2-+3*26%
&ishio$a S;, Silviera /9/, >auab ;, >ite Mar$s are useful for the differential diagnosis
of sna$ebite in >ra4il. Hournal of ilderness Medicine *++-C (6)" *:3*
&orris 8, >ite mar$s and the diagnosis of venomous sna$ebite. Hournal of ildernessMedicine *++-C (6)" *-+3*6*
/aul 9, /ratibha S, /rahlad ;, @arali H, rancis S, 8e!is , 'igh3Bose ;nti3Sna$e9enom versus lo! dose anti3sna$e venom in the treatment of poisonous sna$ebites I ;
critical study Hournal of the ;ssociations of /hysicians of ndia 200%C-2" *%3*1
/aul 9, /rahlad ;, @arali H, rancis S, 8e!is .Trial of heparin in viper bites. H ;ssoc/hysicians ndia. 200:C-*"*6:36.
/eshin SS, 8all S>, alee$al T, Sna$e @nvenomations n @d 8all S> Management of=ommon ndian Sna$e V nsect >ites *++1 &ational /oisons nformation =entre ;MS
Belhi.
/illay 99, Modern medical Toicology 200- @ditors Haypee >rothers &e! Belhi.
/rema!ardenha ;, de Silva =@, onse$a MMB, ?unatila$ee S>, de Silva 'H, 8o! dose
subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in peoplebitten by sna$es" randomised, placebo controlled trial >MH. *+++C :*" *0%*3*0%:
eit4, =.H.. >oomslang bite33time of onset of clinical envenomation.
S. ;fr. Med. H. *++C16" :+3%0.
Sampson ';, Mendelson 8, osen H/. atal and near3fatal anaphylactic reactions to foodin children and adolescents. & @ngl H Med *++2C:21":03%.
Simons @, ?u G, Simons H. @pinephrine absorption in adults" intramuscular versus
subcutaneous in
-
8/10/2019 Snakebite Treatment Protocol
35/37
Simpson B. Sna$ebite Management in ndia, The irst e! 'ours" ; ?uide for /rimary
=are /hysicians. H ndian Med ;ssoc 2001C*0-":2%3::-
Srimannanarayana H, Butta T, Sahai ;, >adrinath S, ational Fse of ;nti3sna$e venom
(;S9)" Trial of various egimens in 'emotoic Sna$e @nvenomation H;/. 200%C-2"
131+:
Thea$ston B, 8loyd3Hones MH, eid ';, EMico3@lisa for detecting and ;ssaying Sna$e
9enom and ;ntibodyA 8ancet *+11C (2)"6:+3%*
Thea$ston B, /hillips @, arrell B;, ?alagedera , ;beyse$era, BT, Bissanaya$a /,
de Silva ;, ;loysius BH, @nvenoming by the =ommon rait (>ungarus caeruleus) and
Sri 8an$an =obra (&a
-
8/10/2019 Snakebite Treatment Protocol
36/37
en an ', Marcopito 8, =ardoso H8=, ranca 7S, Mala#ue =MS, errari ;,
Thea$ston B, arrell B;, Se#uential randomised and double blind trial of
/rometha4ine prophylais against early anaphylactic reactions to antivenom for >othropssna$e bites. >MH. *+++C (:*)"*%-*3*%-:
-
8/10/2019 Snakebite Treatment Protocol
37/37
A))endi;
S#))ort Factors to 'nhance Snakebite Protocols
Snakes o6 Medical Signi6icance
ndian venomous sna$es of medical significance have usually been regarded as only four
species" ussells 9iper, Sa! Scaled 9iper, =obra and rait. These species !ere believed
to be causing all fatalities in ndia. 'o!ever this concept has led to some seriousproblems"
*. ;S9 Manufacturers only produce antivenom against these species2. The assumption that only EThe E>ig %A can cause serious symptoms and death has
led to mis3identification of species.
:. 7ther deadly sna$es may be going un3noticed and causing death and disability5The recent discovery of the 'ump3nosed /itviper as a species capable of causing
life threatening symptoms has demonstrated this.
n order to determine the actual list of medically significant species in ndia, the old
concept of EThe >ig ourA is to be abandoned for a ne!er more fleible model that
enables better classification of species. The .'.7. Model, produced in *+*, has been
adopted as the ndian preferred method for categorising sna$es of medical importance.The model is sho!n belo!"
Sna$es of Medical Significance based on (.'.7. *+*)
Class I"Commonl( ca#se death or serio#s disabilit(
FSS@88S 9/@=7>;S; S=;8@B 9/@
Class II"